Assessing bioequivalence of generic modified-release antiepileptic drugs
نویسندگان
چکیده
منابع مشابه
Bioequivalence of generic drugs.
Generic drugs are bioequivalent to the original brand; this is a prerequisite for marketing approval. It is theoretically possible that one generic drug may overestimate the pharmacokinetic (PK) parameters of the original and another generic may underestimate these PK parameters; in consequence, these 2 generics may not be bioequivalent between themselves. The result could be loss of efficacy o...
متن کاملAntiepileptic drugs: the drawbacks of generic substitution.
The need to curb the rising costs of health care has led policy-makers in many countries to consider widespread generic substitution of brand-name drugs as an eff ective means to cut costs. For example, on January 5, 2010, the NHS in England began a 3-month consultation to seek views on plans to automatically substitute branded drugs with generic versions in primary care. However, doctors, pati...
متن کاملAssessing suicidal risk with antiepileptic drugs
Recently, the US Food and Drug Administration issued an alert about an increased risk for suicidality during treatment with antiepileptic drugs (AEDs) for different indications, including epilepsy. We discuss the issue of suicide in epilepsy with special attention to AEDs and the assessment of suicide in people with epilepsy. It has been suggested that early medical treatment with AEDs might po...
متن کاملTherapeutic equivalency of generic antiepileptic drugs: results of a survey.
Controversy persists whether generic antiepileptic drugs (AEDs) are interchangeable with brand name drugs with respect to efficacy and adverse events. Three hundred and one neurologists responded to a survey regarding generic AEDs mailed to 6420 neurologists, for an overall response rate of 4.7%. One hundred and ninety-six (67.8%) neurologists reported breakthrough seizures after a switch from ...
متن کاملGeneric substitution of antiepileptic drugs: What's a clinician to do?
Generic substitution of antiepileptic drugs remains a controversial area without a clear consensus to guide clinicians. The US Food and Drug Administration (FDA) requires rigorous testing of generic products and states that all approved products are interchangeable. FDA studies involve single doses in normal subjects so may not represent the performance of generic products in people with epilep...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2016
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0000000000002607